Suppr超能文献

实时聚合酶链反应、高通量下一代测序和 Biocartis Idylla™ 平台在非小细胞肺癌中表皮生长因子受体突变检测周转时间和一致性的比较。

Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.

机构信息

Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, Haryana, India.

Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, Odisha, India.

出版信息

Pathol Res Pract. 2021 Apr;220:153394. doi: 10.1016/j.prp.2021.153394. Epub 2021 Mar 3.

Abstract

OBJECTIVES

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene of non-small cell lung carcinomas (NSCLC) can be targeted by the tyrosine kinase inhibitors. A number of molecular diagnostic platforms are used to detect actionable targets in the exon(s) 18, 19, 20, and 21 of the EGFR gene. The Idylla™ system (Biocartis, Mechelen, Belgium) is a relatively novel technique and is unique in integrating both sample processing and real-time polymerase chain reaction (RT-PCR) in a single cartridge. We sought to conduct this study to compare the turnaround time (TAT) and concordance of Idylla™ system with the conventional RT-PCR and next-generation sequencing (NGS) for EGFR mutation detection.

METHODS

In this retrospective analysis, 38 formalin-fixed, paraffin-embedded NSCLC tissue blocks with known NGS results by Ion Torrent™ S5 NGS platform were retested by the RT-PCR and Idylla™ platforms.

RESULTS

A total of 15 of 38 (39.4 %) tumors that showed various EGFR mutations by NGS and conventional RT-PCR techniques were subjected to the Idylla™testing. These cases satisfied the specimen adequacy criteria of at least 10 % tumor cells for the testing. The mutations detected by the NGS were also detected by the Idylla™ testing. However, NGS identified additional 3 mutations in 3 cases, involving T709 V (exon 18, n = 1) and V774 M (exon 20, n = 2). The tumors with wild type EGFR on NGS did not have any actionable mutation detected by the Idylla™. Average EGFR testing TAT by Idylla™ was only 7.2 h (4-12 hours), as compared to conventional RT-PCR taking 54 h (31-79 hours) and NGS requiring 10.7 days (7.1-14 days). The actual procedure time by conventional RT-PCR was 24 h, NGS was 6.5 days, and Idylla™ was only 3 h.

CONCLUSIONS

In summary, the Idylla™EGFR testing is an efficient, rapid, and fairly simple tool that can be used in the routine molecular laboratory with limited expertise and infrastructure and using the lowest amount of tissue material.

摘要

目的

非小细胞肺癌(NSCLC)中表皮生长因子受体(EGFR)酪氨酸激酶结构域的激活突变可以被酪氨酸激酶抑制剂靶向。许多分子诊断平台用于检测 EGFR 基因外显子 18、19、20 和 21 中的可操作靶标。IdyllaTM 系统(Biocartis,比利时 Mechelen)是一种相对较新的技术,其独特之处在于将样本处理和实时聚合酶链反应(RT-PCR)集成到一个试剂盒中。我们旨在进行这项研究,以比较 IdyllaTM 系统与传统 RT-PCR 和下一代测序(NGS)在 EGFR 突变检测中的周转时间(TAT)和一致性。

方法

在这项回顾性分析中,38 个福尔马林固定、石蜡包埋的 NSCLC 组织块通过 Ion TorrentTM S5 NGS 平台进行了已知 NGS 结果的检测,然后通过 RT-PCR 和 IdyllaTM 平台进行了重新检测。

结果

共有 15 例(39.4%)肿瘤通过 NGS 和传统 RT-PCR 技术显示出各种 EGFR 突变,通过 IdyllaTM 进行了检测。这些病例符合检测至少 10%肿瘤细胞的标本充足标准。NGS 检测到的突变也通过 IdyllaTM 检测到。然而,NGS 在 3 例中额外检测到 3 个突变,涉及 T709V(外显子 18,n=1)和 V774M(外显子 20,n=2)。NGS 显示 EGFR 野生型的肿瘤未通过 IdyllaTM 检测到任何可操作的突变。IdyllaTM 进行的平均 EGFR 检测 TAT 仅为 7.2 小时(4-12 小时),而传统 RT-PCR 为 54 小时(31-79 小时),NGS 需要 10.7 天(7.1-14 天)。传统 RT-PCR 的实际操作时间为 24 小时,NGS 为 6.5 天,而 IdyllaTM 仅为 3 小时。

结论

总之,IdyllaTM EGFR 检测是一种高效、快速且相当简单的工具,可以在具有有限专业知识和基础设施的常规分子实验室中使用,并使用最少的组织材料。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验